Predictive Oncology (NASDAQ:POAI) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened
Predictive Oncology Q4 Earnings Call Highlights
Predictive Oncology (NASDAQ:POAI) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened
Predictive Oncology (NASDAQ:POAI) versus Mitesco (OTCMKTS:MITI) Head-To-Head Comparison
Financial Analysis: Predictive Oncology (NASDAQ:POAI) and Healthcare Triangle (NASDAQ:HCTI)
Predictive Oncology (NASDAQ:POAI) Shares Cross Below 200-Day Moving Average – Here’s What Happened
Predictive Oncology Becomes Axe Compute, Expanding Into High-Performance AI Infrastructure
Predictive Oncology Inc. (POAI) Q3 2025 Earnings Call Prepared Remarks Transcript
Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy
Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy
Predictive Oncology Inc. Announces Closing of $343.5 Million in Private Placements to Initiate Digital Asset Treasury Strategy
Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens
Predictive Oncology Announces 1-for-15 Reverse Stock Split
Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients
PREDICTIVE ONCOLOGY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
Court Denies Renovaro Motion for an Expedited Trial in July
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
Predictive Oncology Closes Registered Direct Offering
Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing
Certis Oncology Announces Issuance of U.S. Patent for Its Proprietary CertisAI Predictive Oncology Intelligence™ Platform
Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay
PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
POAI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Predictive Oncology Inc. Is Fair to Shareholders
Renovaro to Acquire Predictive Oncology in All-Stock Transaction
Predictive Oncology Announces Agreement to be Acquired by Renovaro
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update
Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Predictive Oncology Inc. (POAI) Q2 2024 Earnings Call Transcript
Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update
Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
Why Is Predictive Oncology (POAI) Stock Up 70% Today?
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024
Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Predictive Oncology Inc. (POAI) Q1 2024 Earnings Call Transcript
Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update
Predictive Oncology to Report First Quarter 2024 Financial Results on Wednesday, May 15, 2024